Kyowa Hakko Kirin Co., Ltd.
Basic information
- Head office
- 1-9-2 Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan, Otemachi Financial City Gran Cube
- Chief executive
- Abdul Malik
- Capital
- 26,745,000,000 JPY (267 100 millionJPY)
- Employees (non-consolidated)
- Employees (consolidated)
- 5,161 people
- Start date
- 1949-07-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
| 協和キリングループ |
Network
History
Streptomycin manufacturing technology was introduced from Merck in the United States, and the first mass production of streptomycin in Japan was achieved. It contributed to the eradication of tuberculosis. (Initiation of pharmaceutical business activities)![]()
Successfully isolated mitomycin C, an antitumor agent, and industrialized it. Invented the first L-glutamic acid production technology using fermentation, pioneering the large-scale amino acid fermentation industry.![]()
Released the neutropenia treatment drug "Gran®" (G-CSF formulation). Released the hypertension and angina treatment drug "Conir®."![]()
With the introduction of Kirin Beer Co., Ltd.'s pure holding company structure, "Kirin Pharma Co., Ltd." was founded. Released the sustained-release erythropoietin-stimulating agent "Nesup®." Established the new technology "COMPLEGENT®" to enhance antibody pharmaceutical activity.![]()
Released the secondary hyperparathyroidism treatment drug "Regpar® tablets." Split the biochemicals business and established Kyowa Hakko Bio Co., Ltd. Founded Kyowa Hakko Kirin Co., Ltd.![]()
Released the platelet-stimulating agent/thrombopoietin receptor agonist "Romiplate® subcutaneous 250 µg formulation." Acquired the UK company ProStrakan.![]()
Founded the joint venture "Kyowa Kirin Fujifilm Biologics Co., Ltd." for development, manufacturing, and sales of biosimilar drugs with Fujifilm. Released the adult T-cell leukemia/lymphoma (ATL) treatment drug "Poteligo® IV infusion 20 mg."![]()
UK-based ProStrakan acquired Archimedes. Sustained-release G-CSF product "GiraSTA® subcutaneous 3.6mg" launched.![]()
X-linked hypophosphatemia treatment Crysvita® approved in Europe and the U.S. Cystic papilloma and Cezary syndrome treatment Poteligeo® approved in Europe and the U.S.![]()
Company renamed to Kohwa Kirin Co., Ltd. Kyowa KIRIN FGF23-related hypophosphatemic disease treatment Crysvita® launched in Japan. Parkinson's disease treatment Nourianz™ launched in the U.S.![]()
Cystic papilloma and Cezary syndrome treatment Poteligeo® launched in Europe. Crysvita® received additional indication approval for tumor-induced osteomalacia (TIO) in the U.S.![]()
New vision for 2030 formulated, aiming for life-changing value. Joint development and sales agreement with Amgen for human anti-OX40 monoclonal antibody KHK4083. Expressed support for TCFD recommendations.![]()
Global DE&I declaration formulated, aiming for 40% female leadership by 2030. GiraSTA® subcutaneous 3.6mg body pod launched in Japan. Q-TOWER bio‑pharmaceutical analysis facility completed at the Hirosaki plant.![]()
Domestic approval for high‑phosphatemia treatment Fozebel® obtained. Acquisition of UK-based Orchard Therapeutics plc, a company with hematopoietic stem cell gene‑therapy technology, announced.![]()
News
There is no news.